Change of address for BLA submissions
As of Oct. 4, all therapeutic biologic submissions excluding 21 CFR 600.80 postmarketing adverse experience reports; advertising and promotional labeling; and 21 CFR 600.14 biological product deviation reports should be sent to CDER Therapeutic Biological Products Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 12229 Wilkins Ave., Rockville, MD 20852. FDA hopes to continue its normal pace of review, but "I do anticipate that it might slow things down a little bit," CDER Office of Compliance Therapeutics Facilities Review Branch Facility Reviewer Carolyn Renshaw said during the PDA/FDA Regulatory Conference in Washington, D.C. Sept. 22. "There is going to be a transition period. I do believe it will be difficult mailing and getting everything on time, which was difficult to begin with"...
You may also be interested in...
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.